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Enhancing enterocyte fatty acid 
oxidation in mice affects glycemic 
control depending on dietary fat
Deepti Ramachandran1, Rosmarie Clara1, Shahana Fedele1, Ladina Michel1, 
Johannes Burkard1, Sharon Kaufman1, Abdiel Alvarado Diaz2, Nadja Weissfeld1,  
Katrien De Bock2, Carina Prip-Buus3,4,5, Wolfgang Langhans1 & Abdelhak Mansouri  1
Studies indicate that modulating enterocyte metabolism might affect whole body glucose homeostasis 
and the development of diet-induced obesity (DIO). We tested whether enhancing enterocyte fatty 
acid oxidation (FAO) could protect mice from DIO and impaired glycemic control. To this end, we used 
mice expressing a mutant form of carnitine palmitoyltransferase-1a (CPT1mt), insensitive to inhibition 
by malonyl-CoA, in their enterocytes (iCPT1mt) and fed them low-fat control diet (CD) or high-fat diet 
(HFD) chronically. CPT1mt expression led to an upregulation of FAO in the enterocytes. On CD, iCPT1mt 
mice had impaired glycemic control and showed concomitant activation of lipogenesis, glycolysis and 
gluconeogenesis in their enterocytes. On HFD, both iCPT1mt and control mice developed DIO, but 
iCPT1mt mice showed improved glycemic control and reduced visceral fat mass. Together these data 
indicate that modulating enterocyte metabolism in iCPT1mt mice affects glycemic control in a body 
weight-independent, but dietary fat-dependent manner.
Obesity and its related comorbidities, such as type-2-diabetes (T2D), hypertension, and cardiovascular disease, 
are major global health concerns1. With a rise in the consumption of western diets, and with decreasing physical 
activity, the incidence of obesity is increasing world over. Currently, the only treatments for morbid obesity that 
lead to sustained weight loss are invasive and costly interventions such as gastric bypass surgery2. The success of 
these surgical procedures comes with several unresolved side effects, including malabsorption of essential micro-
nutrients and early or late post-surgical complications2. Interestingly, one of the consistent benefits of bariatric 
surgeries is improved glycemic control based on a reversal of insulin resistance (IR). These improvements are 
seen even before any noticeable weight loss3. Results from gastric bypass rodent models as well as human patients 
suggest that these almost immediate improvements are due to functional and/or morphological changes in the 
small intestine4,5.
Previous pharmacological studies in rodents implicated enhanced fatty acid oxidation (FAO) in the small 
intestine in the control of eating6–8. We recently reported evidence that a constitutive overexpression of the mito-
chondrial protein Sirtuin 3 (SIRT3) in mouse enterocytes was associated with enhanced FAO and ketogenesis 
and reduced fatty acid synthesis in these cells when the mice were fed a fat-rich diet9. Interestingly, constitutive 
enterocyte SIRT3 overexpression had no effect on daily food intake and did not protect the mice from developing 
diet-induced obesity (DIO), but did protect them from developing IR. SIRT3, however, is a post-translational 
regulator of several other pathways in addition to FAO, including reactive oxygen species (ROS) scavenging, the 
tri-carboxylic acid (TCA) cycle, urea cycle and ketogenesis10.
To more specifically upregulate FAO in mouse enterocytes, we used the CPT1mt protein, a mutated form of the 
rat carnitine palmitoyltransferase-1a (CPT1a) enzyme that is insensitive to its endogenous inhibitor malonyl-CoA11. 
Several studies have used the CPT1mt protein in vitro as well as in vivo to enhance mitochondrial FAO flux in tar-
get cells or tissues12–17. We crossed the established transgenic mouse line with a floxed STOP cassette preceding 
the Cpt1mt gene (Cpt1mtfl/fl)17 with the Villin-Cre mouse line (Vil-Cre+/−)18 to generate mice with a homozy-
gous expression of CPT1mt in the enterocytes (iCPT1mt). We isolated primary enterocytes from the duodenum 
and jejunum of these mice to test the metabolic flux of these cells. We fed iCPT1mt and Cpt1mtfl/fl mice a low-fat 
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control diet (CD) or a high-fat diet (HFD) for several weeks, and phenotyped them to determine whether entero-
cyte CPT1mt expression could protect these mice from developing impaired glucose homeostasis, IR and DIO.
Materials and Methods
Animals. Transgenic mice on the C57Bl6N background homozygous for the Cpt1mt construct, loxP - 
STOP cassette - loxP - Cpt1mt (Cptmtfl/fl)17 were crossed with mice on a C57Bl6J background with hemizygous 
expression of Cre recombinase under the Villin promoter (VilCre+/−)18 to generate mice hemizygous for both 
the Cpt1mt gene and the Villin-Cre gene (Cptmtfl/-/ VilCre+/−). These mice were backcrossed with the paren-
tal line Cptmfl/fl to generate male mice homozygous for the Cpt1mt floxed cassette and hemizygous for Villin-
Cre (Cptmtfl/fl/VilCre+/− or iCPT1mt) expressing CPT1mt specifically in the epithelial cells of the intestine. The 
Cptmtfl/fl male littermates served as controls. All mice were genotyped immediately after weaning (at 3 to 4 weeks 
of age) and recaged in groups (2–4 mice/cage) such that only mice with the same genotype shared cages. All 
breedings were carried out in our in-house specified and opportunistic pathogen free (SOPF) facility. At 10 to 12 
weeks of age, mice were moved into the experimental room with controlled temperature and humidity (22 ± 1 °C, 
55 ± 5%) and a reversed 12 h/12 h dark/light cycle (lights off at 8 am). Animals had ad libitum access to food and 
water unless otherwise specified. All animal experimental protocols were performed in accordance with the Swiss 
animal welfare legislation, and approved by the Cantonal Veterinary Office of Zurich.
Diet. Mice in the SOPF breeding facility were fed autoclaved chow diet (#3807, Kliba). After 1–2 weeks of 
adaptation to experimental room conditions, all experimental mice were fed either standard chow (#3430, Kliba), 
refined control diet (CD, #S9213-E001, 10% of energy from fat) or high-fat diet (HFD, #E15742-34, 60% of energy 
from fat) from Ssniff Spezialdiäten GmbH.
Body weight measurements. Body weights of mice fed CD and HFD were monitored regularly in the 
dark phase as indicated using a generic weighing scale.
Insulin sensitivity test (IST). Mice were fasted for 5–6 h in the middle of the dark phase with ad libitum 
access to water. Actrapid HM human insulin (Novo Nordisk) was injected intraperitoneally (IP), and tail blood 
glucose was monitored at the indicated time points using the Accu-Chek Aviva blood glucose monitor (Roche). 
Insulin dose: 0.4 mU/g body weight (CD) and 0.8 mU/g body weight (HFD)19.
Oral glucose tolerance test (OGTT). After a 6 h fast from dark phase onset with ad libitum access to 
water20 mice received a 20% glucose solution by gavage (solvent: water, glucose dose: 2 g/kg body weight). Tail 
blood glucose was monitored at the time points indicated.
Intraperitoneal glucose tolerance test (IPGTT). After a 6 h fast from dark phase onset with ad libitum 
access to water20 mice were injected IP with a 20% glucose solution (solvent: 0.9% saline, glucose dose: 2 g/kg 
body weight). Tail blood glucose was monitored at the time points indicated.
Body composition. Mice were scanned under isoflurane anesthesia using a high-resolution micro computed 
tomography (CT) scanner (La Theta LCT-100; Hitachi-Aloka Medical Ltd), to determine body composition and 
fat distribution.
Indirect calorimetry. Measurements were carried out using the Phenomaster/Labmaster metabolic cages 
(TSE systems). Mice were adapted to single housing in cages similar to the Phenomaster cages for at least one 
week prior to measurements. Data displayed were collected after additional 2 days of habituation in the system.
Animal sacrifice and tissue collection. Mice were food deprived for 2 h prior to sacrifice unless speci-
fied otherwise. All animals were sacrificed in the dark phase by decapitation, and trunk blood was collected in 
tubes containing 0.5 M EDTA. The blood samples were centrifuged at 8,700 g for 10 min at 4 °C, and plasma was 
collected and stored at −80 °C until required. The intestine and liver were dissected out. Intestinal samples were 
further processed as described below, and the liver was flash frozen in liquid nitrogen and stored at −80 °C until 
required. Enterocytes were isolated using a modified protocol described earlier9,21 using 12.5 mL distritip maxi 
syringes (#F164120, Gilson) and ice-cold Cell Recovery solution (#354253, Corning). The cells were scraped into 
ice cold PBS, pelleted and pellets were snap frozen in liquid nitrogen and stored at −80 °C until required.
Primary enterocyte FAO assay. Fifteen to 20-week-old iCPT1mt and CPT1mtfl/fl mice were fasted over-
night. Enterocytes were isolated as described above and scraped into ice cold petri dishes containing DMEM 
(#A1443001, Gibco, ThermoFisher) supplemented with 100 U/mL penicillin and streptomycin (pen-strep), 
1 × N-2 supplement, 1 × B-27 supplement, 10 µM Y-27632 and 2 µM N-acetyl cysteine (NAC) and phenol red 
(basal medium). These cells were then transferred to a 50 mL tube and centrifuged at 500 g for 6 min at room tem-
perature. The cell pellet was resuspended in pre-warmed 0.25% trypsin-EDTA and incubated in a 37 °C, 5% CO2 
incubator for 7 min. An equal volume of soybean trypsin inhibitor (#T6414, SIGMA) containing 20 µM Y-27632 
was then added to neutralize trypsin activity. The cells were filtered successively through 100 µ and 40 µ filters. 
The filtrate was kept on ice, the cells were counted, and an appropriate number of cells was collected in a 2 mL 
Eppendorf tube, centrifuged at 500 g for 5 min and the resulting pellet was resuspended in ice cold basal medium. 
An equal volume of ice cold growth factor reduced Matrigel (#354230, Corning) diluted 1:2 in the same medium 
(to an effective concentration of approximately 5 mg/mL) was added to these cells so that the final concentration 
of matrigel in the cell suspension was 1:4 (2.5 mg/mL). 250000 (250 K) cells were plated per well in 40 µL of 1:4 
matrigel in a regular 96 well cell culture plate. The plate was incubated on ice for 20 min for the cells to settle down 
through the viscous matrigel, then transferred to a 37 °C, 5% CO2 incubator for 20 min for the matrigel to solidify. 
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Basal medium was further supplemented with 1.2 × glucose, L-carnitine, fatty acid free BSA, cold palmitic acid 
and hot (3H-9,10)-palmitic acid, now termed as FAO assay medium. Prewarmed FAO assay medium was added 
to each well (210 µL medium per well) such that each well now had a total volume of 250 µL of medium with a 
final (1×) concentration of 2.5 mM glucose, 500 µM L-carnitine, 50 µM fatty acid free BSA, 100 µM cold palmitic 
acid and 2 µCi/ml of hot (3H-9,10)-palmitic acid. The cells were incubated for 5 h in a 37 °C, 5% CO2 incubator. 
Subsequently, 200 µL of medium from each well was transferred into a glass vial and 50 µL of 3 M perchloric acid 
was added to each vial to stop any metabolic activity. Each vial was closed with a rubber stopper equipped with 
a hanging well containing a filter paper (1 × 6 cm; #3030-931, Whatman) soaked in 200 µL of water, and then 
the vials were incubated for 48 h at 37 °C. The filter paper was then carefully transferred into a scintillation vial 
containing 5 mL of Ultima Gold scintillation fluid (#6013329, Perkin Elmer) along with 100 µL of water used to 
wash any condensation in the hanging well. The disintegrations per minute were recorded using the 2000CA liq-
uid scintillation analyzer (Tri-Carb). The FAO assay medium containing cold plus hot palmitic acid was used to 
generate a standard curve using which the FAO flux was calculated from the disintegrations per minute for each 
sample. Enterocytes from 3 animals were pooled for each genotype (biological replicates) and the n values in the 
figure legends refer to technical replicates.
Primary enterocyte extracellular flux analysis. Primary enterocytes were subjected to metabolic flux 
analysis using the extracellular flux analyzer XFe96 (Agilent Seahorse XF technology) subsequently referred to 
as the “seahorse”. Enterocytes, from 15- to 20-week old iCPT1mt and CPT1mtfl/fl mice fasted overnight, were 
isolated as described above and scraped into a petri dish containing DMEM (#A1443001, Gibco, ThermoFisher) 
supplemented with 5 mM glucose, 100 U/mL pen-strep, 1 × glutamax, 1 × sodium pyruvate, 1 × N-2 supplement, 
1 × B-27 supplement, 10 µM Y-27632 (ROCK inhibitor) and 2 µM NAC. The dissociated and filtered cells were 
counted, centrifuged at 500 g for 6 min and an appropriate number of cells were resuspended in Krebs-Henseleit 
Buffer (KHB) containing 111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, 1.2 mM NaH2PO4 supple-
mented with 100 U/mL pen-strep, 1 × N-2 supplement, 1 × B-27 supplement, 10 µM Y27632 and 2 µM NAC, pH 
7.4) further referred to as experimental medium. The cells were plated into the 96 well seahorse cell plate kept 
on ice so that each well was seeded with 250 K cells in a volume of 20 µL of 1:4 matrigel diluted in experimental 
medium. The plate was incubated on ice for 20 min and in a 37 °C, 5% CO2 incubator for 20 min. Pre-warmed 
experimental medium (160 µL) was then added to each well. The cells were incubated in a CO2 free incubator 
at 37 °C for 30 min while the machine was calibrated. Basal oxygen consumption rate (OCR) and extracellu-
lar acidification rate (ECAR) were measured by the seahorse analyzer followed by the mitochondrial stress test 
using appropriate concentrations (see figure legends) of the respiratory poisons Oligomycin (Oligo), Carbonyl 
cyanide-4-phenylhydrazone (FCCP), Antimycin and Rotenone (Anti + Rot) as indicated. It should be noted that 
some wells showed a leak from one or more of the B, C or D ports of the cartridge due to capillary action initiated 
by the medium from the wells touching the ports of the cartridge during the mixing process. We believe that this 
occurred due to the consistency and thickness of the volume of matrigel in the measurement chamber. These wells 
were easily identifiable by their decrease in OCR due to oligo or Anti + Rot leak or an increase in OCR due to an 
FCCP leak even when no compounds were injected into the ports. These wells were eliminated from the analysis. 
For every parameter we used the average of the three time points measured after the relevant injection/treatment 
using the equations described below22.
= +
=
−
=
−
=
−
= −
= −
‐
‐
‐
‐
Non mitochondrial respiration Average of three OCRmeasurements after Anti Rot
Basal OCR Average of three OCRmeasurements after glucose
Non mitochondrial respiration
Maximal respiration Average of three OCRmeasurements after FCCP
Non mitochondrial respiration
Proton leak Average of three OCRmeasurements after oligomycin
Non mitochondrial respiration
Respiration linked toATP synthesis Basal OCR Proton leak
Spare respiratory capacity Maximal respiration Basal OCR
Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the glycolytic stress test using the 
averages of the three measurements made after the appropriate compound injection as described earlier23 as well 
as in the manufacturer’s protocol. In brief, glycolytic flux refers to the difference between the mean of measure-
ments after glucose injection and baseline values. Glycolytic capacity refers to the difference between the mean 
measurements after oligo injection and baseline values, and glycolytic reserve refers to the difference between the 
mean measurements after oligo injection and after glucose injection. Each well represented a biological replicate 
of 1, while the n values in the figure legends refer to technical replicates.
Western blotting. Tissue samples were processed for western blotting as described earlier16. Briefly, the 
samples were lysed in RIPA buffer, protein concentrations estimated and denatured in Laemmli buffer contain-
ing DTT. Equal amounts of protein samples were run in SDS-PAGE gels and blotted onto PVDF membranes 
and probed using primary antibodies for CPT1a24, HMGCS2 (#sc-33828, Santa Cruz Biotechnology) and 
β-actin (#A2228, Sigma) and the appropriate HRP-linked secondary antibody. The blots were developed using 
an in-house chemiluminescence-based detection kit and analyzed using the ImageQuant LAS 4000 mini (GE 
Health Care).
www.nature.com/scientificreports/
4SciEnTific REpoRtS |  (2018) 8:10818  | DOI:10.1038/s41598-018-29139-6
Histology - H&E stain. Two cm pieces of the duodenum and jejunum, and 1 cm3 liver samples were col-
lected and processed for paraffin embedding and H&E staining as described earlier9.
RT-qPCR analysis. RNA was extracted from tissue samples using the Trizol reagent (#15596018, Life 
Technologies) following the manufacturer’s protocol and treated with DNAse (#79254, Quiagen). cDNA was 
synthesized using the High-Capacity cDNA Reverse Transcription Kit (#4368813, Applied Biosystems) and used 
for real time quantitative PCR (RT-qPCR) reactions using FAST SYBR green and the Viia7 Real Time PCR system 
(Applied Biosystems). Each sample was run in triplicate and the best duplicates or triplicates were analyzed using 
the 2−∆∆CT method25 with Ppib as the reference gene26. Primers used are listed in Sup Table 1.
Statistical analysis. All data were analyzed using GraphPad Prism (version 7.0.2) or IBM SPSS statistics 
(version 23). Outliers were identified using the Grubb’s test and removed. Data normality was verified using 
the Shapiro-Wilk test (when n ≥ 7) and Kolmogorov-Smirnov test (when 5 ≤ n ≤ 6). Parametric data was ana-
lyzed using an unpaired Student’s t-test (two-tailed) or 2 × 2 factorial parametric analysis of variance followed by 
Sidak’s multiple comparison post hoc test whenever appropriate or a mixed repeated measures ANOVA followed 
by a simple effects analysis in the case of a significant interaction or a univariate ANCOVA. The nonparametric 
test (Mann-Whitney) was used when the data did not meet the criteria of normal distribution. Statistical tests 
used and P-values are mentioned in the figure legends. P-values less than 0.05 were considered significant.
Results
iCPT1mt mice show increased CPT1a expression in the intestine, but not in the liver. Western 
blot analysis of tissue samples from Cpt1mtfl/fl and iCPT1mt mice fed CD and HFD indicated that the CPT1mt 
protein was expressed in the enterocytes of the duodenum and jejunum, but not in the liver of iCPT1mt mice 
(P < 0.0001 for CD duodenum and jejunum; P < 0.05 for HFD duodenum and jejunum) (Fig. 1A,B).
Primary enterocytes from iCPT1mt mice have a higher rate of FAO, mitochondrial respira-
tion and glycolysis than Cpt1mtfl/fl control mice. Primary enterocytes isolated from iCPT1mt mice 
fed standard chow showed an increased flux of palmitate oxidation in the duodenum and jejunum compared 
to Cpt1mtfl/fl mice (P < 0.05) (Fig. 2A). When fed HFD for 3 days, primary enterocytes from the duodenum 
of iCPT1mt mice showed a lower rate of palmitate oxidation compared to Cpt1mtfl/fl mice (P < 0.001), but the 
enterocytes from the jejunum of iCPT1mt mice showed an enhanced palmitate oxidation rate compared to con-
trols (P < 0.0001) (Fig. 2A). In a mitochondrial stress test with the seahorse analyzer, primary enterocytes isolated 
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Figure 1. iCPTmt mice show increased CPT1a expression in the intestine, but not in the liver. Western blot 
analysis for carnitine palmitoyltransferase-1, liver isoform (CPT1a) and β-actin protein expression from tissue 
samples of Cpt1mtfl/fl and iCPT1mt mice fed control diet (CD) or high-fat diet (HFD) for 20 weeks. (A) Western 
blot bands from the duodenum, jejunum and liver. (B) Quantification of band intensities. (n = 4 to 5, Unpaired 
t test; *P < 0.05 and ****P < 0.0001 for duodenum CD and HFD, jejunum CD and liver CD and HFD; Mann-
Whitney test; *P < 0.05 for jejunum HFD). Data are presented as mean values ± SEM.
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from the duodenum and jejunum of iCPT1mt mice fed standard chow showed an increased basal and maximal 
(P < 0.0001) as well as increased respiration rate linked to ATP synthesis, proton leak (P < 0.001) and increased 
spare respiratory capacity (P < 0.01) (Fig. 2B,C) compared to primary enterocytes from Cpt1mtfl/fl mice. The 
basal extracellular acidification rate (ECAR) of enterocytes from these chow-fed iCPT1mt mice was also higher 
than that of cells from Cpt1mtfl/fl controls (P < 0.0001) (Sup Fig. 1A,B) as well as after the addition of oligomycin 
(P < 0.01) (Sup Fig. 1A,B). The addition of 2-deoxyglucose (2-DG), the competitive inhibitor of the enzyme 
hexokinase (HK1), abrogated the increased maximal respiration as well as the increase in ECAR seen after the 
addition of glucose, oligomycin and FCCP in these cells (Sup Fig. 1C). Enterocytes from iCPT1mt mice fed stand-
ard chow diet have an increased rate of glycolysis (P < 0.05), glycolytic capacity (P < 0.05) and glycolytic reserve 
(P < 0.05) (Sup Fig. 1C,D).
Intestinal CPT1mt expression reduces visceral fat with HFD feeding without affecting body 
weight gain. HFD feeding increased body weight (significant after 1 week, P < 0.0001), lean body mass 
(P < 0.0001) and subcutaneous fat mass (P < 0.0001) (microcomputed tomography (CT) measurement after 19 
weeks on the diets) compared to CD feeding in all mice irrespective of genotype (Fig. 3A,B). Total fat mass and 
visceral fat mass showed an interaction effect (P < 0.05, diet x genotype for both) such that iCPT1mt mice had less 
visceral fat than Cpt1mtfl/fl mice when fed HFD for 19 weeks (P < 0.05) (Fig. 3B).
A morphological analysis of the small intestine of iCPT1mt and Cpt1mtfl/fl mice fed CD or HFD revealed an 
interaction effect in the villi lengths of their duodenum (P < 0.05, diet x genotype), such that iCPT1mt mice on 
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Figure 2. Primary enterocytes from iCPT1mt mice have a higher rate of FAO, mitochondrial respiration and 
glycolysis than Cpt1mtfl/fl control mice. (A) Rate of oxidation of H3-Palmitic acid by of 250000 (250 K) primary 
enterocytes isolated from the duodenum or jejunum of Cpt1mtfl/fl and iCPT1mt mice. Left two bars: Mice fed 
standard chow. Right two bars: Mice fed HFD for 3 days (n = 5–6, Unpaired t test, *P < 0.05, ***P < 0.001, 
****P < 0.0001). (B) Oxygen consumption rate (OCR) of primary enterocytes per well, isolated from the 
(duodenum + jejunum) of Cpt1mtfl/fl and iCPT1mt mice, incubated in KHB medium and subsequently injected 
with KHB medium or with an effective concentration of 5 mM glucose, 10 µg/mL Oligomycin (Oligo), 8 µmol/L 
FCCP and 5 µg/mL antimycin + 3.75 µmol/L rotenone (Anti + Rot). (C) Basal respiration, respiration linked to 
ATP synthesis, maximal respiration, proton leak and spare respiratory capacity of cells in B (n = 5–6, Unpaired t 
test, **P < 0.01, ***P < 0.001, ****P < 0.0001). (A) Enterocytes from 3 animals were pooled for each genotype 
(biological replicates) and the n values refer to technical replicates. (B,C) Each well represents a biological 
replicate of 1, while the n values refer to technical replicates. The data represent values from two independent 
experiments pooled together. (A–C) Data are presented as mean values ± SEM.
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CD had longer duodenal villi compared to Cpt1mtfl/fl mice (P < 0.05) (Fig. 3C,D). HFD feeding led to an increase 
in the length of villi in the jejunum of all mice (P < 0.01) compared to CD feeding, with no genotype effects 
(Fig. 3C,D). The livers of these mice showed no genotype differences, but all mice on HFD, irrespective of geno-
type, showed markers of hepatic steatosis compared to CD fed mice (Fig. 3C).
iCPT1mt mice and Cpt1mtfl/fl control mice show similar energy intake and whole body energy 
metabolism when fed CD and when switched to HFD. Both iCPT1mt and Cpt1mtfl/fl mice showed a 
similar decrease in the respiratory exchange ratio (RER) (P < 0.0001) when switched from CD to HFD feeding 
(Fig. 4A). No differences were observed in daily energy intake (Fig. 4B), energy expenditure (Fig. 4C) or locomo-
tor activity (Fig. 4D) between the genotypes or on either of the two diets.
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Figure 3. Intestinal CPT1mt expression reduces visceral fat with HFD feeding without affecting body weight 
gain. (A) Body weights of Cpt1mtfl/fl and iCPT1mt mice on CD or HFD monitored over time (n = 11–17; 
Mixed- repeated measures (RM) ANOVA (time x diet x genotype), ****P < 0.0001 for interaction effects of diet 
x genotype ($)). (B) CT scan analyses of Cpt1mtfl/fl and iCPT1mt mice fed CD or HFD for 19 weeks (n = 5–10; 
2 × 2 factorial ANOVA (diet x genotype). *P < 0.05, ****P < 0.0001 for main effect of diet and post hoc tests 
(dashed lines) and interaction effects of diet x genotype ($). (C) Representative bright field microscopy images 
of H&E stained duodenum, jejunum and liver sections of Cpt1mtfl/fl and iCPT1mt mice fed CD or HFD for 20 
weeks at 20X magnification. The yellow bar represents a 100 μm scale. (D) Measurements of the villi lengths 
of Cpt1mtfl/fl and iCPT1mt mice from H&E stained sections. Left: Duodenum, Right: Jejunum (n = 3–5; 2 × 2 
factorial ANOVA (diet x genotype). *P < 0.05, **P < 0.01 for main effect of diet and post hoc tests (dashed 
lines) and interaction effects of diet x genotype ($)). (A,B,D) Data are presented as mean values ± SEM.
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Intestinal CPT1mt expression compromises glycemic control on the CD, but improves it over 
time on HFD. An insulin sensitivity test (IST) on iCPT1mt and Cpt1mtfl/fl control mice fed CD or HFD 
for 12 weeks did not reveal any differences between the two genotypes (Fig. 5A). Both HFD-fed iCPT1mt and 
Cpt1mtfl/fl mice had developed IR as indicated by the increased baseline glucose levels (Fig. 5B). An oral glucose 
tolerance test (OGTT) after 13 weeks on the diets revealed that iCPT1mt mice on CD had impaired glucose 
clearance compared to Cpt1mtfl/fl control mice (P < 0.01, time x genotype) (Fig. 5C). A pairwise comparison at 
each time point showed that iCPT1mt mice had higher circulating glucose levels compared to Cpt1mtfl/fl mice, 
at every time point measured post glucose gavage (at t = 15 and 120 min, P < 0.05; at t = 30, P < 0.0001; at t = 60 
and 90 min, P < 0.01). With HFD feeding, iCPT1mt mice also showed impaired glucose tolerance compared to 
Cpt1mtfl/fl mice, though with a smaller difference between the two genotypes (Fig. 5D, time x genotype, P < 0.05), 
with iCPT1mt mice showing higher circulating glucose levels at 30 min (P < 0.01) and 120 min (P < 0.05) post 
glucose gavage.
After 16 weeks on the diets, mice fed CD continued to show a similar difference, with iCPT1mt mice exhibit-
ing higher levels of circulating glucose in an intraperitoneal GTT (IPGTT) (P < 0.01, time x genotype) (Fig. 5E), 
specifically at 30 (P < 0.05) and 60 min (P < 0.01) post IP glucose injection. HFD-fed iCPT1mt mice, however, 
showed a reversal of glucose tolerance in the IPGTT. iCPT1mt mice cleared the IP-injected glucose better than 
Cpt1mtfl/fl mice (P < 0.01, time x genotype) (Fig. 5F), with lower glycemia at 30 (P < 0.05), 60 (P < 0.01), 90 
(P < 0.01) and 120 min (P < 0.01) post glucose injection.
iCPT1mt mice have reduced circulating non-esterified fatty acid (NEFA) levels compared to 
Cpt1mtfl/fl control mice. An analysis of circulating post-prandial plasma metabolites after 20 weeks on CD 
or HFD revealed a main effect of diet such that all HFD-fed mice showed lower levels of circulating triacylglycerol 
(TAG) (P < 0.0001), β-hydroxybutyrate (BHB) (P < 0.05) and NEFA (P < 0.0001) than mice on CD (Fig. 6A–C). 
Plasma NEFA levels also showed a main effect of genotype (P < 0.05), but the post hoc tests did not reveal a sig-
nificant difference between the genotypes on either diet (Fig. 6C). Plasma cholesterol as well as plasma glucose 
levels were higher in all HFD-fed mice than in CD-fed mice, irrespective of genotype (P < 0.0001) (Fig. 6D–E).
iCPT1mt mice on CD, but not on HFD, show an upregulation of fatty acid synthesis, glycolysis 
and gluconeogenic genes in jejunal enterocytes compared to Cpt1mtfl/fl mice. Gene expression 
analyses of the jejunal enterocytes of iCPT1mt and Cpt1mtfl/fl mice after 20 weeks on CD and HFD revealed 
increased expression of genes involved in fatty acid uptake (Fat/cd36) (P < 0.001), fatty acid binding (Fabp1), 
FAO (Lcad), ketogenesis (Hmgcs2) (P < 0.0001) and malonyl-CoA synthesis (Acc2) (P < 0.0001) in all HFD-fed 
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Figure 4. iCPT1mt mice and Cpt1mtfl/fl control mice show similar energy intake and whole body energy 
metabolism when fed CD and when switched to HFD. (A–D) Indirect calorimetry data of Cpt1mtfl/fl and 
iCPT1mt mice on CD for 48 h and HFD for the next 48 h. The grey and white bars in the background represent 
the periods of dark and light phases respectively. The dashed lines indicate when the mice were switched from 
CD to HFD feeding. (A) Respiratory exchange ratio as mean values of 1 h bins. (B) Cumulative energy intake 
in 1 h bins. (C) Energy expenditure (EE) as mean values of 1 h bins. (D) Locomotor activity as mean values of 
1 h bins. (n = 8–11, Mixed RM ANOVA (diet × time × genotype, repeated measures for time and diet for A,B 
and D; ANCOVA for mean values per day with BW as the covariate for C). (A–D) Data are presented as mean 
values ± SEM.
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mice compared to CD-fed mice (Fig. 7, Sup Fig. 2 and Sup Table 1). The genes involved in glucose absorption 
through the apical enterocyte membrane (Sglt1) (P < 0.0001), glycolysis (Hk1) (P < 0.05) and de novo fatty acid 
synthesis (Acc1) (P < 0.0001) were downregulated in all HFD-fed mice compared to CD-fed mice (Fig. 7 and Sup 
Table 1). Genes involved in mitochondrial biogenesis were downregulated (Pgc1a) (P < 0.0001), or remained 
unchanged (Tfam) in all HFD-fed mice compared to CD-fed mice, irrespective of genotype. All iCPT1mt mice 
showed an upregulation of glycolysis (Hk1), fatty acid binding (Fabp2) (P < 0.05), de novo fatty acid synthesis 
(Fasn (P < 0.01) and Acc1 (P < 0.001)) compared to Cpt1mtfl/fl mice, and post hoc tests revealed that these effects 
were significant on the CD (P < 0.05 for Hk1, Fabp2 and Fasn; P < 0.01 for Acc1). The gluconeogenic gene phos-
phoenolpyruvate carboxykinase 1 (Pepck1) showed an interaction effect in the jejunum (P < 0.01, diet x genotype) 
such that Pepck1 was upregulated in the CD-fed iCPT1mt mice compared to Cpt1mtfl/fl mice (P < 0.05), with no 
difference between the genotypes when fed HFD (Fig. 7, Sup Fig. 2 and Sup Table 1).
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Figure 5. Intestinal CPT1mt expression compromises glycemic control on the CD, but improves it over time 
on HFD. (A,B) Insulin sensitivity test (IST) for Cpt1mtfl/fl and iCPT1mt mice on CD and HFD, respectively. (A) 
Left: Tail blood glucose values for CD-fed mice at the time points indicated (n = 10–13). (B) Left: Tail blood 
glucose values for HFD-fed mice at the time points indicated. Right: Area above the curve (AAC) for the data 
on the left (n = 16–17). (C-D) Oral glucose tolerance test (OGTT) for Cpt1mtfl/fl and iCPT1mt on CD and HFD 
respectively. (C) Left: Tail blood glucose values for CD-fed mice at the time points indicated. Right: Area under 
the curve (AUC) for the data on the left (n = 11–15). (D) Left: Tail blood glucose values for HFD-fed mice at 
the time points indicated. Right: Area under the curve (AUC) for the data on the left (n = 11–15). (E–F) Intra-
peritoneal glucose tolerance test (IPGTT) for Cpt1mtfl/fl and iCPT1mt on CD and HFD respectively. (E) Left: 
Tail blood glucose values for CD-fed mice at the time points indicated. Right: Area under the curve (AUC) 
for the data on the left (n = 11–15). (F) Left: Tail blood glucose values for HFD-fed mice at the time points 
indicated. Right: Area under the curve (AUC) for the data on the left (n = 11–15). (A–F) Mixed RM ANOVA 
(time x genotype) with repeated measures for time for the line graphs and unpaired t test for the bar graphs. 
*P < 0.05, **P < 0.05, ***P < 0.001, ****P < 0.0001 for main effect of genotype and simple effects analysis 
of genotype at each time point in the case of a significant interaction between time and genotype ($). Data are 
presented as mean values ± SEM.
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The duodenal enterocytes of all HFD-fed mice showed increased expression of Lcad, Hmgcs2, Fat/cd36, Fabp1, 
Fabp2, Acc2 (P < 0.0001) and Fasn (P < 0.05) and reduced expression of Pgc1a (P < 0.0001) compared to CD-fed 
mice (Sup Fig. 2). The expressions of Pgc1a (P < 0.05) and Acc2 (P < 0.01) were further downregulated in all 
iCPT1mt mice compared to Cpt1mtfl/fl controls, and a post hoc test showed that this effect was significant for 
Pgc1a in iCPT1mt mice fed CD (P < 0.05) and for Acc2 in iCPT1mt mice fed HFD (P < 0.01) (Sup Fig. 2). Acc1 
showed a genotype effect (P < 0.05), but the post hoc comparisons were not significant when compared within 
each diet (Sup Fig. 2). Expression of Sglt1 showed an interaction effect (P < 0.01, diet x genotype) with its levels 
specifically upregulated in iCPT1mt mice fed CD (P < 0.01) (Sup Fig. 2).
The livers of iCPT1mt and Cpt1mtfl/fl mainly showed an upregulation of all the genes tested in HFD-fed mice, 
compared to those fed CD (P < 0.05 for Hmgcs2, P < 0.01 for Fasn and P < 0.0001 for the other genes), except for 
Pgc1a and Pepck1, which showed no differences between the genotypes or diets (Sup Fig. 3). A western blot anal-
ysis of these tissue samples showed that protein level of the ketogenic marker HMGCS2 was downregulated in the 
duodenal and jejunal enterocytes but not in the liver of iCPT1mt mice on CD (P < 0.01 for duodenum, P < 0.05 
for jejunum). HMGCS2 protein levels were also downregulated in the jejunal enterocytes (P < 0.05), but not in 
the duodenal enterocytes or in the liver, of HFD-fed iCPT1mt mice compared to Cpt1mtfl/fl controls (Sup Fig. 4).
Discussion
Studies using pharmacological approaches in rodents suggest that metabolic changes in the small intestine can reduce 
food intake and hence improve DIO6,7. Metabolic changes in the intestine may also contribute to the improvements 
in glucose homeostasis seen immediately after bariatric surgery in humans and rodents4. Here we report that entero-
cyte CPT1mt expression impaired glycemic control in CD-fed mice, but improved it in HFD-fed mice. These effects 
were independent of changes in body weight, but were accompanied by increased expressions of genes involved in 
fatty acid synthesis, glucose uptake, glycolysis and gluconeogenesis, especially in CD-fed iCPT1mt mice.
Using a previously established method, we isolated primary enterocytes from iCPT1mt and Cpt1mtfl/fl mice9,21 
and successfully processed and embedded them in a diluted matrigel matrix such that we could study their met-
abolic flux in vitro. The increased FAO flux in enterocytes isolated from chow-fed iCPT1mt mice compared to 
those from Cpt1mtfl/fl mice is consistent with previous studies in which the CPT1mt protein was expressed in 
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Figure 6. iCPT1mt mice have reduced circulating non-esterified fatty acid (NEFA) levels compared to 
Cpt1mtfl/fl control mice. (A–E) Post prandial trunk blood plasma metabolite levels of Cpt1mtfl/fl and iCPT1mt 
mice on CD and HFD. (A) Triacylglycerol (TAG). (B) β-hydroxybutyrate (BHB). (C) Non-esterified fatty acids 
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values ± SEM.
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different tissues or cell types12–17. Together these results suggest that the enterocytes of iCPT1mt mice are capable 
of oxidizing more fatty acids than the enterocytes of control Cpt1mtfl/fl mice when fed a low-fat diet. When fed 
HFD, the jejunal enterocytes of iCPT1mt can enhance their FAO capacity even further. A direct comparison is 
not possible between the FAO rates of enterocytes from chow and HFD fed mice because they were performed as 
independent experiments. Visually though, HFD feeding for 3 days seemed to increase the FAO flux of both duo-
denal and jejunal enterocytes of Cpt1mtfl/fl mice and only the jejunal enterocytes of iCPT1mt mice. This is con-
sistent with previous data from our lab, which showed that the gene expression of FAO enzymes was upregulated 
in the duodenum and jejunum of wildtype mice fed HFD for 3 days23. As for the decrease in the FAO rate in the 
duodenum of iCPT1mt mice compared to Cpt1mtfl/fl mice, we speculate that the expression of CPT1mt protein 
may have maximized the FAO capacity of these cells, and they were not able to extend this capacity further at least 
after 3 days of HFD, but this remains to be tested.
The extracellular flux analysis revealed that pooled duodenal and jejunal enterocytes of chow-fed iCPT1mt 
mice had an overall increased basal metabolism, in the absence of any added substrate in the medium, compared 
to enterocytes from Cpt1mtfl/fl mice. Providing glucose increased the rate of glycolysis and mitochondrial respi-
ration in enterocytes from iCPT1mt mice, indicating that their glycolytic as well as oxidative respiration capacity 
were upregulated compared to enterocytes from Cpt1mtfl/fl mice. It would be interesting to see how HFD feeding 
would affect these metabolic fluxes.
At the whole body level, we saw no differences in body weight gain between iCPT1mt and Cpt1mtfl/fl mice 
when fed CD or HFD for up to 20 weeks. This is similar to what we observed in intestinal SIRT3 overexpressing 
(iSIRT3) mice9, suggesting that increasing FAO flux in the enterocytes of mice does not cause a change in body 
weight gain. A body composition analysis revealed, however, that HFD-fed obese iCPT1mt mice had less visceral 
fat than Cpt1mtfl/fl mice. Both iCPT1mt and Cpt1mtfl/fl control mice showed similar changes in postprandial 
circulating TAG, BHB, cholesterol and glucose levels when fed HFD vs CD. These effects were similar to those 
seen in iSIRT3 mice on HFD and CD, and were consistent with the species-specific effects observed in long-term 
HFD-fed mice27,28. We saw no genotype differences in energy intake or energy homeostasis when the mice were 
fed CD or switched to HFD. This was also similar to our findings in iSIRT3 mice9, indicating that a constitutive 
upregulation of FAO in the enterocytes does not affect energy intake or whole body energy metabolism. It would 
be interesting to see how the energy metabolism in these mice might change after feeding them CD or HFD for 
several weeks.
Both iCPT1mt and Cpt1mtfl/fl control mice showed similar responses to exogenous insulin after 12 weeks of 
CD or HFD feeding. iCPT1mt mice however responded differently to exogenous glucose depending on the diet, 
the route of glucose administration and/or the duration of CD or HFD feeding. These differences could be related 
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Figure 7. iCPT1mt mice on CD show an upregulation of fatty acid synthesis, glycolysis and gluconeogenic 
genes in jejunal enterocytes compared to Cpt1mtfl/fl mice. Relative mRNA expression of genes in the jejunum of 
Cpt1mtfl/fl and iCPT1mt mice fed CD or HFD for 20 weeks (n = 6–10, 2 × 2 factorial ANOVA (diet x genotype). 
*P < 0.05, **P < 0.001, ***P < 0.001, ****P < 0.0001 for main effects of diet or genotype (g) and post hoc tests 
(dashed lines) and interaction effects of diet x genotype ($). Data are presented as mean values ± SEM.
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to the mode of glucose administration, but may also indicate that adult iCPT1mt mice that may have already been 
intolerant to glucose, slowly reversed this phenotype when fed HFD chronically. If so, it may explain why the 
iCPT1mt mice were still comparatively intolerant to exogenous glucose after 13 weeks on HFD, but had reversed 
this phenotype by 16 weeks. The idea of a biphasic response of glucose intolerance in HFD fed C57Bl6 mice 
seen after 3 days of HFD feeding and then between 12 to 16 weeks of HFD feeding fits with our idea of a gradual 
change in glucose tolerance29. The reduced visceral fat mass in HFD-fed iCPT1mt mice could also be involved in 
the improved glucose tolerance, since visceral fat is well known to be associated with the incidence of metabolic 
syndrome30. These results were partly similar and partly different from our findings in iSIRT3 mice. Enterocyte 
overexpression of SIRT3 had no effect in mice fed CD but did protect them from developing IR and glucose intol-
erance under conditions of DIO9.
Expressions of genes for fatty acid binding and fatty acid synthesis were upregulated specifically in iCPT1mt 
mice compared to Cpt1mtfl/fl controls on CD. This could indicate that CPT1mt expression in the jejunal entero-
cytes led to increased de novo fatty acid synthesis in these cells, perhaps to funnel fatty acids into the mito-
chondria for the constitutively active FAO. This assumption is consistent with data from isolated rat hepatocytes 
expressing the CPT1mt protein. Even in the presence of high glucose and insulin that favor lipogenesis, these cells 
were able to oxidize de novo synthesized LCFA12.
Interestingly, the glycolytic gene Hk1 was upregulated in the jejunal enterocytes of iCPT1mt mice fed CD. This 
is consistent with the seahorse data from isolated enterocytes, which showed that enterocytes from iCPT1mt mice 
had a higher rate of glycolysis than enterocytes from Cpt1mtfl/fl mice when provided with glucose. Mitochondrial 
acetyl-CoA generated via FAO cannot directly leave the mitochondria and fuel fatty acid synthesis. It needs to 
enter the TCA cycle to generate citrate, which can then leave the mitochondria via the citrate shuttle to fuel de 
novo lipogenesis31. The pyruvate derived from enhanced glycolysis undergoes oxidative decarboxylation, and the 
resulting Acetyl-CoA also enters the mitochondria to fuel the TCA cycle. When TCA cycle intermediates become 
limiting, accumulating mitochondrial acetyl-CoA form ketone bodies. In the enterocytes of CD-fed iCPT1mt 
mice, however, the protein levels of ketogenic HMGCS2 were significantly downregulated. Therefore, we would 
favor the hypothesis that the accumulating acetyl-CoA could be funneled into the TCA cycle which would even-
tually fuel lipogenesis. Interestingly, the expression of the gluconeogenic gene Pepck1 was also increased in the 
jejunal enterocytes of iCPT1mt mice, indicating that these cells were producing glucose. Together these results 
indicate that the jejunal enterocytes of CD-fed iCPT1mt mice might have developed futile cycles of FAO and 
lipogenesis, as well as glycolysis and gluconeogenesis.
Concomitantly, in the duodenal enterocytes of CD-fed iCPT1mt mice, we saw an increase in Sglt1 expression. 
SGLT1 is the glucose transporter in the apical membrane that absorbs glucose from the intestinal lumen, thus 
supporting the idea of increased glucose absorption. The increased villi length in the duodenum of iCPT1mt 
mice fed CD as well as the higher levels of blood glucose seen in iCPT1mt mice, 15 minutes after oral, but not 
IP glucose bolus support the idea of increased glucose absorption from the intestine of iCPT1mt mice fed CD.
On HFD, all mice showed an overall increase in the expressions of genes related to fatty acid uptake, fatty 
acid binding, FAO and ketogenesis in their duodenal and jejunal enterocytes. Expressions of genes related to glu-
cose absorption, glycolysis and gluconeogenesis were either downregulated in all mice or remained unchanged. 
Together these results indicate that the futile cycles generated in CD-fed iCPT1mt mice were absent in HFD-fed 
mice. How these enterocyte metabolic changes might affect whole body glucose homeostasis is still unclear.
In iSIRT3 mice fed HFD, increased ketogenesis in the small intestine was associated with the improved insulin 
sensitivity and glucose tolerance9. In iCPT1mt mice, however, HMGCS2 protein levels were significantly lower 
and circulating BHB levels were unchanged, indicating that these effects on improved glycemic control were 
unrelated to ketogenesis. We believe that the increased glucose absorption in the duodenum and the upregulated 
gluconeogenesis in the jejunum might contribute to the reduced glucose tolerance seen in iCPT1mt mice fed CD. 
Unlike hepatic gluconeogenesis that is inhibited by insulin, intestinal gluconeogenesis is known to be enhanced 
in the post absorptive period32. The enhanced intestinal gluconeogenesis supposedly provides more glucose for 
hepatic portal vein glucose sensors that may signal the brain to inhibit eating as reviewed in33. Perhaps the higher 
glucose levels observed in the OGTT and IPGTT are the result of substantially enhanced glucose absorption and/
or gluconeogenesis in the enterocytes of iCPT1mt mice. Another possible explanation is that the permanently 
enhanced gluconeogenesis and glycolysis in the enterocytes of iCPT1mt mice fed CD limits their capacity to utilize 
large oral or intraperitoneal loads of glucose properly, leading to impaired glycemic control. Data from rodent 
models show that gluconeogenesis in the gut can contribute anywhere from 5 to 25% of whole body endoge-
nous glucose production depending on the diet as reviewed in34. Mice with a liver specific or liver and intestinal 
specific knock out of the gluconeogenic gene glucose-6-phosphatase, catalytic subunit (G6pc) showed that in 
the absence of hepatic gluconeogenesis, intestinal gluconeogenesis is essential to maintain physiological levels 
of blood glycemia35. Together these data indicate that changes in enterocyte metabolism can contribute to and 
influence systemic glucose concentrations substantially, which supports our idea that enterocyte gluconeogenesis 
is capable of contributing to the glycemic dysregulation we see in iCPT1mt mice.
Perhaps on HFD, iCPT1mt mice have enough LCFA and carbohydrate intermediates to fuel the constitutive 
upregulation of FAO and the TCA cycle and therefore do not need a massive upregulation of glucose absorption 
or gluconeogenesis to fuel the de novo synthesis of fatty acids. The constitutive upregulation of FAO under these 
conditions could slowly reverse the adverse effects seen under CD fed conditions. It would be interesting to see 
whether iCPT1mt mice might be prevented from developing DIO and/or impaired glycemia if they were directly 
weaned onto the HFD. Consistent with this idea hepatic CPT1mt expression was able to prevent the development 
of DIO and IR in adult mice fed HFHS diet after the expression of CPT1mt using an adeno-associated virus14. 
Also both hepatic and skeletal muscle expressions of CPT1mt were able to reverse already established IR and 
impaired glycemia in DIO mouse models without affecting body weight15,17. In fact, these studies did not show 
any adverse effects of CPT1mt expression in mice fed standard chow. The main difference between these mouse 
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models and our intestinal transgenic mice, other than the obvious difference in the organs we targeted, is that our 
mice express CPT1mt constitutively from embryonic development, whereas in these other models the CPT1mt 
expression was induced in adulthood. An inducible Villin-Cre model, in which we could specifically express 
CPT1mt in the mouse enterocytes in adulthood, might provide a clearer picture to whether an upregulation of 
enterocyte FAO would protect from the development of DIO and IR, without the negative effects seen on CD.
The declining slope in the OCR of the enterocytes seen in the mitochondrial stress test was most likely due to a 
decrease in cell viability over time. Previous studies with intestinal crypts, organoids or intestinal stem cells in the 
seahorse also showed similar declines in the OCR over time36,37. We believe that this was a drawback of embed-
ding primary enterocytes in a 3D layer of diluted matrigel. We would like to emphasize, however, that the present 
study represents the first successful attempt to analyze the bioenergetics of live primary enterocytes from adult 
rodents. As epithelial cells, enterocytes are notoriously difficult to culture alive and especially as single cells. In 
our attempts to culture these cells, we performed several trial experiments with different cell surface attachment 
protocols, all of which led to steep declines in the OCR of the enterocytes. The method of embedding the cells in 
matrigel was the only one that worked and gave a consistently, but comparatively slowly and similarly decreasing 
slope in every experiment. We also tested different dilutions of matrigel to determine the best conditions under 
which we were able to achieve a consistent range of OCR as well as a consistent slope.
In sum, these results show that persistent changes in mouse enterocyte FAO do not influence daily energy 
intake or energy homeostasis and body weight, but affect whole body glucose homeostasis under different dietary 
conditions. Further studies should try to elucidate the exact mechanism of these effects and dissociate the contri-
bution of the molecular and metabolic changes in the gut versus other organs.
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